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The efficacy of pre-exposure prophylaxis, a preventative strategy based on the use of antiretroviral 
drugs to block HIV acquisition, has been demonstrated in four different clinical trials: CAPRISA004, 
iPrEx, TDF2, and Partners PrEP. These studies, although different in design and target populations, 
showed that the utilization of such a preventive strategy is highly protective. In contrast, VOICE 
(Vaginal and Oral Interventions to Control the Epidemic) and Fem-PrEP studies led to the opposite 
conclusion. These conflicting results are likely due to low adherence to the study drug. In VOICE, for 
example, the plasma concentration of tenofovir, the protective drug, was detectable in less than 40% 
of the enrolled women. 
To evaluate the real’ effect of the drug, it is imperative to use an analytical method that takes 
participant adherence to the study protocol into account. But this is not the whole story. In fact, while 
we can discriminate between adherers and non-adherers in the drug study arm, we cannot easily 
differentiate between these groups in the placebo arm. Comparing adherers in the drug arm to non-
adherers in the drug arm can be confounding. What if the subjects that adhered to the drug are also 
those less exposed to HIV? In such a situation, we would be comparing apples and oranges. This is 
likely the case for the two dissenting studies. In the same VOICE study, in fact, women that were 
less likely to adhere to the drug were younger and unmarried, with a higher risk score for HIV 
acquisition.  Furthermore, while conventional statistical wisdom is to remove confounding by 
adjusting for confounding variables in regression models, unmeasured confounding is always 
possible.  
August 17, 2015 SCIENCE SPOTLIGHT 
 
2 Volume 5, Issue 8 | Fred Hutchinson Cancer Research Center 
 
Dr. James Dai at the Vaccine and Infectious Disease Division at Fred Hutch undertook this 
challenge and published a statistical method that allows investigators to assess whether their 
covariate adjustments are adequate to remove confounding errors. The method is built upon a 
reasonable assumption, known as “ exclusion restriction”  in the causal inference literature, that 
those with no pharmacological evidence of adherence should not receive protection from ARV. The 
paper was published last month on the Journal of Infectious Diseases. 
Dr. Dai applied his method to the results obtained from the VOICE study, which was designed to 
evaluate the efficacies of a gel formulation and two oral regimens of tenofovir (TDF), alone or in 
combination with emtricitabine (FTC/TDF). For the comparison between tenofovir gel and placebo, 
adjusting for a set of confounding variables related to HIV exposure largely removed the selection 
bias. Gel use was shown to result in a 47% reduction of HIV infection. In contrast, the same 
adjustment for the oral TDF and FTC/TDF arm analyses did not show adequate confounding control. 
Moreover, no protection was shown for either of them. The difference between the gel and oral 
formulation results might be explained by the fact that oral administration of the drug results in a 
much higher plasma concentration, so that the laboratory cutoff used to discriminate between 
adherers and non-adherers might be suitable for gel but too low to prove continuous use of the drug 
for oral treatment. 
"Inferring causal effect among adherers is a challenging task in randomized clinical trials. The new 
regression analysis strategy we proposed for assessing prevention effect among adherers suggests 
evidence of protection against HIV infection among gel users in the VOICE study," said Dr. Dai. The 
same analysis could be useful for future efficacy trials not only testing PrEP but also other 
prophylactic and therapeutic strategies. 
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